The global preclinical imaging market is expected to grow significantly, reaching an estimated value of US$ 3,332.2 million by 2033. This growth is driven by increased research and development activities in cell and gene therapies, as well as the rising adoption of high-throughput in-vivo imaging technologies. Additionally, advancements in artificial intelligence (AI) have facilitated the development of multimodal imaging platforms, enhancing the capabilities and applications of preclinical imaging.
Leading companies in this market include Bruker, Siemens Healthineers, and Fujifilm, which continue to innovate and expand their offerings to meet the growing demand for non-invasive, high-resolution imaging solutions. These technologies are playing a crucial role in accelerating drug discovery and improving the understanding of disease mechanisms.
**Why this matters**
Preclinical imaging is essential for early-stage drug development and biomedical research, providing detailed insights into biological processes without invasive procedures. The integration of AI and multimodal platforms is expected to improve imaging accuracy and efficiency, supporting faster and more effective therapeutic advancements. As investment in cell and gene therapy research increases, the demand for sophisticated imaging tools will likely continue to rise, influencing the future landscape of medical research and development.
Source: NewsData